enGene Therapeutics Inc (ENGN) — Titan Protect Analysis

ENGN

enGene Therapeutics Inc

Healthcare · ·

$1.64

Data: 2026-06-03

✓ ETHICAL PASS

NONE MOAT

LIMITED

Data Confidence: 0.0%

Key Metrics

How this company measures up on the fundamentals that matter

Market Cap

$114M

Total market value of the company

Trailing P/E

N/A

Forward P/E

-0.85

Based on estimated future earnings — lower means cheaper

Rev Growth

N/A

Year-over-year revenue change

Profit Margin

N/A

How much profit the company keeps from each dollar of revenue

ROE

-46.1%

Return on equity — how efficiently it uses shareholder money

Analyst Target

$4.00

+144% from current price — median analyst estimate

Recommendation

NONE

Consensus view from 7 analysts covering this stock

About enGene Therapeutics Inc

enGene Therapeutics Inc., through its subsidiary enGene, Inc., operates as a clinical-stage biotechnology company in Canada. The company develops genetic medicines to help patients suffering from bladder cancer. Its lead product candidate is detalimogene voraplasmid, a monotherapy for the treatment of non-muscle invasive bladder cancer (NMIBC). Its pipeline includes LEGEND, which is in Phase 2. The company was formerly known as enGene Holdings Inc. and changed its name to enGene Therapeutics Inc

https://www.engene.com

Country: Canada Employees: 81 Industry: Biotechnology

Ethical Screening

Five compliance checks based on AAOIFI standards — all must pass for ethical clearance

Business Activity

PASS

Core business does not involve prohibited activities

Debt Ratio

0.0% PENDING

Debt must be below 33% of total assets

Cash Ratio

0.0% PENDING

Interest-bearing cash below 33% of assets

Receivables

0.0% PENDING

Receivables below 49% of assets

Revenue Purity

0.0% PENDING

Non-compliant revenue below 5% — any excess requires purification

Quantitative Intelligence

Statistical analysis of price behaviour, risk, and market regime — independent of fundamental data

Regime

DISTRIBUTION

Smart money appears to be selling into strength — caution

Sharpe Ratio

0.011

Positive but modest risk-adjusted returns

Kelly Fraction

-0.0199

No positive edge detected — the data suggests staying out

Calmar Ratio

-0.609

Drawdown risk outweighs the returns — higher risk profile

Annual Return

-53.7%

Historical annualised return based on price data

Max Drawdown

-88.2%

Largest peak-to-trough decline — the worst it has been

HMM State

SIDEWAYS

Price consolidating — no clear directional bias

Days in State

How long the current regime has persisted — longer means more stable

Market Data

Trading characteristics and market positioning

Beta

-0.01

Very low correlation to market moves

52W High

$12.25

87% below the year high

52W Low

$1.40

17% above the year low

Avg Volume

1,591,919

Average daily shares traded — higher means easier to buy and sell

Short Ratio

0.5

Days it would take all short sellers to cover — higher means more crowded

Short % Float

N/A

Div Yield

N/A

Annual dividend as a percentage of the share price

EPS (TTM)

$-2.25

Earnings per share over the last 12 months

Financial Health

Balance sheet strength and cash generation — the foundation of long-term value

Debt/Equity

11.89

Heavy leverage — higher financial risk if revenues decline

Current Ratio

N/A

Quick Ratio

N/A

Like current ratio but excludes inventory — stricter test

Gross Margin

N/A

Revenue left after cost of goods — higher means pricing power

Operating Margin

N/A

Profit from core operations before interest and tax

Free Cash Flow

$-65,304,376

Negative — the business is spending more than it generates

Revenue (TTM)

N/A

Total revenue over the last 12 months

Net Income

$-122,438,000

Loss-making — spending exceeds revenue after all costs

Analyst Coverage

Analysts

Target High

$6.00

Target Median

$4.00

Target Low

$2.00

Explore the Ethical Screener View Track Record

Data sourced from public filings and market feeds. Not financial advice. Updated: 2026-06-03

Before you go